Molecular systems engineering at the tumor/immune ... · Aim 3: Measuring and Integrating Tumor &...
Transcript of Molecular systems engineering at the tumor/immune ... · Aim 3: Measuring and Integrating Tumor &...
Aim 3: Measuring and Integrating Tumor & Immune Response to Optimally Target Both
Molecular systems engineering at the tumor/immune interface Aaron S. Meyer, Research Fellow/Principal Investigator
Koch Institute for Integrative Cancer Research, [email protected] http://asmlab.org
Talk: Thurs, Oct 6 at 2:00 Room 200A
Aim 2: Systems Approaches for Rationally Designing Innate Immune Therapies
Aim 1: Identifying Shared Features Among Resistance Mechanisms to Help Predict Effective Combination Therapies for Individual Patients
• Manole, S., E.J. Richards, A.S. Meyer. ``JNK pathway activation modulates acquired resistance to EGFR/HER2 targeted therapies.” Cancer Research. 2016.
• Meyer, A.S., M.A. Miller, F.B. Gertler, D.A. Lauffenburger. “The receptor AXL diversifies EGFR signaling and limits the response to EGFR-targeted inhibitors in triple-negative breast cancer cells.” Science Signaling. 2013 Aug 6; 6(287):ra66.
• Miller, M.A., A.S. Meyer (co-first), M. Beste, Z. Lasisi, S. Reddy, K. Jeng, C.-H. Chen, J. Han, K. Isaacson, L.G. Griffith, D.A. Lauffenburger. “ADAM-10 and -17 regulate endometriotic cell migration via concerted ligand and receptor shedding feedback on kinase signaling.” Proc. Natl. Acad. Sci. U.S.A. 2013 May 28; 110(22):E2074-83.
• Miller, M.A., M.J. Oudin, R.J. Sullivan, D.T. Frederick, A.S. Meyer, S. Wang, H. Im, J. Tadros, L.G. Griffith, H. Lee, R. Weissleder, K.T. Flaherty, F.B. Gertler, D.A. Lauffenburger. “Reduced proteolytic shedding of receptor tyrosine kinases is a post-translational mechanism of kinase inhibitor resistance.” Cancer Discovery. 2016 Apr; 6:331-333.
• Meyer, A.S. (co-corresponding), A.J.M. Zweemer, D.A. Lauffenburger. “The AXL receptor is a sensor of ligand spatial heterogeneity.” Cell Systems. 2015 Nov 29; 1(1):25-36.
• Richards, E.J., S. Manole, A.S. Meyer. “Engineering more precise and potent TAM-targeted therapies.” In preparation.
• Miller, M.A., M. Moss, G. Powell, R. Petrovich, L. Edwards, A.S. Meyer, L.G. Griffith, D.A. Lauffenburger. “Targeting autocrine HB-EGF signaling with specific ADAM12 inhibition using recombinant ADAM12 prodomain.” Scientific Reports. 2015 Oct 19; 5:15150.
• Zweemer, A.J.M., C.B. French, J. Mesfin, S. Gordonov, A.S. Meyer, D.A. Lauffenburger. “Phosphatidylserine-expressing extracellular vesicles induce migration via the AXL receptor.” In preparation.
Survival Survival Survival
A B CX
Original Tumor Bypass Resistance No Resistance ConferredBulk tumor Invasive cells
Dendridic cells
T cellsMacrophages
NK cellsProtein SGas6
Tyro3 AXL MerTK
NIH DIRECTOR’S
EARLY
INDEPENDENCE
AWARD
Days0
50
100
Tum
or v
olum
e (m
m3 )
Days0
50
100
Tum
or v
olum
e (m
m3 )
PLA Combination 1pRTK Combination 2tRTK Combination 3sRTK Combination 4
...
Surv
ival
1.0
0.8
0.6
0.4
0.2
0.0
Days0 10 20 30
PDX models
PLA Combination 1pRTK Combination 2tRTK Combination 3sRTK Combination 4
0 10 20 30
0 10 20 30
HRGβEGFPDGFFGFControlIGFFGFIGFHGFHGFHRGβControlPDGFEGF
pAkt
pcJu
npE
rk1/
2pG
SK3α
/βpP
38pJ
NK
pAkt
pGSK
3α/β
pcJu
npE
rk1/
2pJ
NK
pP38
FGFPDGFControlEGFHRGβHGFIGFHGFEGFControlPDGFFGFHRGβIGF
A PC9 HCC827
3 2 1 0 -1 -2 -3
z-score(Log2(Signal))
GLM regression of viability
Signals
Cond
ition
s
Akt
Erk
GSK
3b
cJun
JNK
P38
Akt
.Erk
HCC827
PC9
HCC827/PC9
B
C p < 0.05
p < 0.01
p < 0.001
Coe�cient: Positive Negative
Overview
Gas6 Spatial Heterogeneity10 -1 10 0 10 1 10 2 10 3
AXL
Act
ivat
ion
0
500
1000
1500
2000
Uniform Gas6 Localized Gas6
Overview of our approach. We will first focus on tumor cell-intrinsic targeted therapy resistance, studying how activation of non-targeted RTKs (bypass activation) leads to resistance (Aim 1). In Aim 2, we will apply data-driven analytical methods to elucidate TAM RTK function and apply these approaches to rationally design innate immune-targeted agents. We will pioneer approaches for measuring and manipulating immune-tumor cell communication in Aim 3 to identify more effective therapeutic combinations targeting both. Each of these areas will take advantage of thorough modeling and experimental integration.
(A) In RTK-driven tumors, signals are transduced from the receptor to various kinases. (B) Upon blocking the original cancer driver, resistance can be conferred by an untargeted receptor. (C) Some receptors, however, do not provide essential resistance signals. By identifying similarities and differences of signaling from each receptor, we will be able to identify measurements pinpointing the relevant receptor causing resistance.
In many cancers, a subset of tumor cells overexpress AXL, making them invasive and resistant to therapy. TAM receptor activation within dendritic cells potently inhibits the innate immune response. T cell release of ProS further dampens the immune response. Activation of TAMs inhibits NK cell-mediated lysis. Each of these cell populations express distinct and dynamic combinations of TAM receptor, likely modulating functional changes in microenvironmental response.
In cancer, multiple factors including efferocytosis and direct signaling lead to an immunosuppressive environment. In contrast, diseases with autoimmune components often involve aberrant cell death and/or cellular clearance, leading to positive feedback disrupting self-tolerance. Through this similarity, studying the signaling and trafficking effects of cellular debris has important implications for both cancer and these diseases.
Aim 2Aim 1
Aim 3
Immune response
Immune response